Roivant Sciences (ROIV) Capital Expenditures (2020 - 2026)
Roivant Sciences' (ROIV) quarterly Capital Expenditures came in at $6.9 million in Q4 2025, up 83.42% YoY from $3.8 million in Q4 2024, and down 11.47% on a QoQ basis from $7.8 million in Q3 2025.
Roivant Sciences (ROIV) Capital Expenditures (2020 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Capital Expenditures data on file, last reported at $6.9 million in Q4 2025.
- Quarterly Capital Expenditures rose 83.42% year-over-year to $6.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $22.6 million (up 233.52% YoY) and the FY2026 annual result came in at $7.4 million, up 61.25% from the prior year.
- Capital Expenditures retreated to $6.9 million in Q4 2025, from $7.8 million in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $11.2 million in Q4 2021 to a low of $275000.0 in Q3 2023.
- A 5-year average of $4.3 million and a median of $3.1 million in 2022 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2023 — Capital Expenditures slumped 94.6% — and 2025, when it soared 687.95%.
- Tracing ROIV's Capital Expenditures over 5 years: stood at $11.2 million in 2021, then declined by 0.94% to $11.1 million in 2022, then tumbled by 90.67% to $1.0 million in 2023, then surged by 266.7% to $3.8 million in 2024, then soared by 83.42% to $6.9 million in 2025.
- The last three Capital Expenditures figures came in at $6.9 million (Q4 2025), $7.8 million (Q3 2025), and $4.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -1.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.87 Mn |
| Jun 30, 2026 | -1.87 Mn |
| Dec 31, 2025 | 6.95 Mn |
| Dec 31, 2025 | 6.95 Mn |
| Sep 30, 2025 | 7.85 Mn |
| Sep 30, 2025 | 7.85 Mn |
| Jun 30, 2025 | 4.04 Mn |
| Jun 30, 2025 | 4.04 Mn |
| Dec 31, 2024 | 3.79 Mn |
| Dec 31, 2024 | 3.79 Mn |
| Sep 30, 2024 | 996,000.00 |
| Sep 30, 2024 | 996,000.00 |
| Jun 30, 2024 | 965,000.00 |
| Jun 30, 2024 | 965,000.00 |
| Dec 31, 2023 | 1.03 Mn |
| Dec 31, 2023 | 1.03 Mn |
| Sep 30, 2023 | 275,000.00 |
| Sep 30, 2023 | 275,000.00 |
| Jun 30, 2023 | 403,000.00 |
| Jun 30, 2023 | 403,000.00 |